Labcorp has announced the nationwide availability of ColoSense, the first FDA-approved RNA-based at-home colorectal cancer (CRC) screening test, through its partnership with Geneoscopy. The launch expands Labcorp’s colorectal cancer screening portfolio and follows CMS’s decision to provide Medicare coverage for eligible beneficiaries. The test is also supported by additional commercial coverage and aligns with recommendations from the American Cancer Society (ACS) and National Comprehensive Cancer Network (NCCN).
ColoSense is designed to improve screening participation by addressing one of the biggest barriers to stool-based testing: sample collection. Unlike traditional stool tests that require handling or mixing the sample, ColoSense uses a simplified collection process that minimizes direct stool handling, making the at-home experience cleaner and easier for patients. The kit is delivered directly to patients’ homes, with Geneoscopy providing navigation support to help complete testing and ensure appropriate follow-up after positive results.